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Abstract
To identify the clinical and pharmacological risk factors associated with tacrolimus 
pharmacodynamics for acute graft- versus- host disease (aGVHD) in pediatric patients 
receiving allogeneic hematopoietic stem cell transplantation (HSCT) from a matched 
related donor. A retrospective cohort single center chart review study was conducted 
with pediatric patients who received tacrolimus prophylaxis after allogeneic HSCT 
between January 1, 2017, and December 31, 2019. Potential risk factors were tested 
separately between aGVHD and non- aGVHD cohorts and were further analyzed in a 
logistic regression model with backward elimination and a partial least squares dis-
criminant analysis. Thirty- three patient cases were included in our study and 52% 
(17/33) developed aGVHD while on tacrolimus prophylaxis. When tested indepen-
dently, donor age and sibling versus parent donor/recipient relation were shown to 
be statistically significant between aGVHD and non- aGVHD patients (p < 0.005). 
Pharmacological factors associated with tacrolimus treatment failed to demonstrate 
a significant impact on patient’s risk of aGVHD. Using a best fit logistic regression 
model that tested all the variables together, donor age was the only significant vari-
able predicting patient’s risk of aGVHD (p < 0.01). Donor relationship and donor 
age were unable to be evaluated separately and are therefore confounding variables. 
Among pediatric patients receiving allogeneic HSCT, aGVHD risk is significantly 
decreased by either sibling donor and/or younger donors. Although no conclusions 
were drawn on the effect of tacrolimus therapy (p = 0.08), results warrant additional 
research with a larger sample size to evaluate the accuracy of monitoring tacrolimus 
serum trough levels.
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is typically 
reserved for life- threatening diseases, such as relapsed acute 
lymphoblastic leukemia and acute myeloblastic leukemia, 
due to severe and life- threatening complications associated 
with the procedure.1 Patients who undergo allogeneic HSCT 
are at significant risk of graft- versus- host- disease (GVHD), a 
debilitating condition where the patient’s immune system re-
acts to the donor’s cells and triggers an inflammatory cascade 
that ultimately results in tissue damage and organ injury. 
GVHD can present acutely or chronically and incidences of 
GVHD in pediatric patients have been reported to be between 
30% and 50%, varying by the type of transplant and the re-
cipient’s relationship to the donor.2 Conditioning the patient 
to have a successful engraftment while minimizing the risk 
of developing GVHD is a delicate balance that remains chal-
lenging in current clinical practice.
Tacrolimus is a calcineurin inhibitor commonly used for 
the prevention of acute GVHD (aGVHD), defined as GVHD 
that occurs within 100 days post- transplant.3 To date, there 
are very limited studies examining the pharmacokinetic 
(PK) profile of tacrolimus in children post solid organ trans-
plant.4,5 These PK studies have demonstrated significant 
interpatient variability in drug exposure. The oral bioavail-
ability of tacrolimus in children ranges even more widely 
from 5% to 93%, with a mean bioavailability of 25% in pa-
tients who have undergone solid organ transplantation.6 Of 
note, pediatric patients who undergo transplantation appear 
to eliminate tacrolimus more rapidly than adult patients who 
undergo transplantation. In patients undergoing HSCT, the 
nonlinear PK model of tacrolimus is further complicated by 
altered hepatic and renal function, and other severe compli-
cations, such as sinusoidal obstructive syndrome, that occur 
after transplantation.
Tacrolimus has a narrow therapeutic index requiring 
close monitoring of its trough levels.7,8 In adult patients 
who undergo transplant, tacrolimus levels are typically 
maintained between 10 and 20  ng/ml.8 However, the 
target levels of tacrolimus in pediatric patients are not 
conclusive and vary in practice among different institu-
tions.9,10 Given the limited information collected from pa-
tient studies, finding a reliable predictive model to guide 
patient care and clinical practice has been challenging.10 
Additional challenges include being able to swiftly reach 
a safe therapeutic serum level using an intravenous for-
mulation and maintaining the target serum levels when 
switching to oral administration, both of which are im-
pacted by the metabolic variability among patients be-
cause tacrolimus is extensively metabolized primarily by 
the hepatic P450 enzymes, such as CYP3A.11 Identifying 
an appropriate dosing method, optimal target serum lev-
els, and time to reach those levels may improve patient 
outcomes, as suggested by Offer et al.10 Ultimately, more 
studies are warranted to evaluate the use of tacrolimus in 
pediatric patients with HSCT and to determine its clini-
cal outcomes, such as patient’s risk of developing GVHD 
post- transplantation.
Previous studies examining risk factors for developing 
aGVHD have determined that one of the most important 
factors is human leukocyte antigen (HLA) disparity, where 
matched grafts have lower rates of aGVHD than HLA- 
mismatched grafts.2 Other factors that may increase the like-
lihood of developing GVHD— acute and chronic— include 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
WHAT QUESTION DID THIS STUDY ADDRESS?
Donor- related clinical factors play a large role in acute graft- versus- host disease 
(aGVHD) development. Accounting for these factors while examining the pharmaco-
logical properties of tacrolimus is understudied in the pediatric setting.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
This study investigated clinical and pharmacological risk factors that may affect 
a pediatric hematopoietic transplant patient’s risk of aGVHD while on tacrolimus 
therapy.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
This study (1) is consistent with other studies in that sibling donors have a lower risk 
of aGVHD than parent donors, and (2) provides exploratory data to guide future stud-
ies that examine the pediatric patient population.
Given the significant interpatient pharmacokinetic (PK) variability, our results sug-
gest that monitoring other PK parameters, such as the area under the curve (AUC) in 
addition to measuring trough levels reduce aGVHD risk in children.
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donor age, sex mismatch, and the myeloablative regimen 
used. Although these risk factors have been largely exam-
ined in the adult setting, only a few studies examined these 
trends in children. Identifying the interaction between these 
risk factors and tacrolimus use on the likelihood of develop-
ing aGVHD in pediatric patients with HSCT is understud-
ied and prompts additional research. Therefore, the purpose 
of this study is to examine the effect of tacrolimus levels on 
developing aGVHD in pediatric patients with HSCT. The 
dose of tacrolimus, the number of days it takes to reach 
target levels, and other patient clinical and demographic 
features have been evaluated as potential risk factors to de-




A retrospective, institutional review board- approved study 
was conducted in patients who underwent HSCT and were 
admitted to a children’s hospital, CHOC Children’s, from 
January 1, 2017, until December 31, 2019. Patients with 
HSCT who were younger than 26  years old and received 
tacrolimus treatment for GVHD prophylaxis were included 
in the study. Each transplant was examined as an individual 
datapoint, meaning some patients were analyzed as multi-
ple datapoints for each time they used tacrolimus as GVHD 
prophylaxis for a transplant. Patients were excluded if they 
died due to a complication separate from aGVHD.
The clinical information was obtained from each patient 
via chart review, which includes age at time of transplant, gen-
der, weight, diagnosis, starting dose, dose by weight, i.v. to 
oral (p.o.) conversion, final p.o. to i.v. ratio (before tapering 
off p.o.), aGVHD status, donor relationship, donor age, liver 
toxicity (liver function tests and bilirubin levels), renal toxicity 
(serum creatinine levels), and the HLA allele match in per-
centage. All trough levels measured within the first 100 days 
post- transplant were collected and the following metrics were 
calculated: the range of the tacrolimus trough levels obtained, 
days to greater than 5 ng/ml on i.v. medication, days to greater 
than 10 ng/ml on i.v., percent of serum trough levels less than 
5 ng/ml, and percent of serum trough levels less than 10 ng/ml. 
Due to the low representation of diagnoses, the patients were 
further grouped into 4 categories in the statistical analysis 
based on clinical relevance: group 1 (acute lymphoblastic leu-
kemia), group 2 (acute myeloid leukemia and GATA2- related 
deficiencies), group 3 (aplastic anemia, beta thalassemia in-
termedia, congenital thrombocytopenia, and sickle cell dis-
ease), and group 4 (Hodgkin’s lymphoma and hemophagocytic 
lymphohistiocytosis).
The donor relation was further divided into sibling, parent, 
or unrelated. Hepatotoxicity was defined by an elevation of 
serum transaminases greater than 5× normal upper level, or a 
serum total bilirubin level greater than or equal to 2.0 mg/dL.12 
Nephrotoxicity was defined as a doubling of serum creatinine 
greater than baseline pretransplant value or a serum creatinine 
greater than 2 mg/dL, which requires renal dose adjustment.13
Statistical analysis
Statistical analysis was done using “The R Project” for scien-
tific computing version 3.6.2.14 A Power analysis for sample 
size calculation was conducted using the data collected, fol-
lowed by additional post hoc t- test power calculations using 
the sample sizes in this study. To investigate variables associ-
ated with aGVHD, each variable was run separately comparing 
the aGVHD group to the non- aGVHD group. A Welch t- test 
was used for continuous variables unless normal distribution 
assumptions were not met, in which case a Wilcoxon Mann– 
Whitney was substituted. A Fisher’s exact test was used for 
categorical variables.
Next, the variables were combined in a logistic regres-
sion. The aGVHD status was the dependent variable with 
the above- mentioned clinical and demographic variables 
as independent. Due to the large number of variables in 
comparison to the number of subjects, an exhaustive algo-
rithm, which investigated all possible combinations of in-
dependent variables, was used to determine the model with 
the lowest Bayesian Information Criterion and the lowest 
Akaike Information Criterion, followed by backward elim-
ination to remove any nonsignificant variables from this 
model.15 Due to computational limitations, the algorithm 
is limited to 15 predictor variables. The 15 variables with 
the strongest relationship to aGVHD status were used in 
the algorithm, however, all remaining variables were added 
during the process of backward elimination and tested for 
inclusion in the final model. Primary results were based on 
this logistic regression method and, therefore, p values were 
not adjusted for the use of multiple statistical tests. Instead, 
confidence intervals were included when possible. In order 
to limit the influence of any confounding variables, a par-
tial least squares discriminant analysis was conducted.16 
This is a supervised learning method that uses the indepen-
dent variables to best predict the outcome of the dependent 
variable, in this case, aGVHD versus non- aGVHD. It is the 
preferred method useful in cases of multicollinearity and 
in data sets where there are many independent variables 
compared with the number of subjects.17 Confounding 
variables are often difficult to determine and can distort the 
results. In our study, we used multiple statistical methods 
to account for multicollinearity.
4 |   PHAN et Al.
RESULTS
Descriptive statistics
This study was a single- center retrospective study con-
ducted at a 334- bed regional academic children’s hospital. 
Approval for the study was received from the institutional 
review board after expedited review. Pediatric patients who 
received HSCT from January 1, 2017, until December 31, 
2019, were identified. Records of 34 pediatric HSCT cases 
were retrospectively reviewed. Thirty- two individual pa-
tients were examined. Of the 32 patients, 2 patients under-
went 2 transplants with tacrolimus prophylaxis, totaling 34 
transplant cases examined in this study. One was excluded 
due to exclusion criteria and a total of 33 transplant cases 
were included in the final analysis.
Our study showed that 52% (17/33) of transplant cases 
developed aGVHD while on tacrolimus prophylaxis treat-
ment (Table 1). The average donor age was 14 years old and 
15 years old for non- aGVHD and aGVHD patients, respec-
tively (p > 0.05). Overall, 64% of transplant cases were with 
male patients (Table 1). On average, patient weight was 58 kg 
and 59 kg for aGVHD and non- aGVHD patients, respectively 
(Table 2). Average patient body weight was also not signif-
icant when independently testing for aGVHD risk. Seventy- 
three percent of the transplants were White patients, with 6% 
being Asian and 21% identifying as “other.” Transplants also 
predominantly used tacrolimus in combination with cyclo-
phosphamide on day 3 and 4 post- transplant and mycophe-
nolate on day 5 for aGVHD prophylaxis, with only 9% using 
a different tacrolimus combination regimen. These patients 
who received a different regimen were those diagnosed with 
aplastic anemia (AA), whereas all four AA transplants re-
ceived different regimens. Two out of the 34 transplants ex-
perienced aGVHD, failed tacrolimus therapy, and switched 
to sirolimus (Table 1).
Thirty of 33 donors were haploidentical. The percentage of 
HLA allele match between the donor and recipients were 58.3% 
and 60.8% on average, respectively, in non- aGVHD and aGVHD 
patients. Of note, the average age of donors in the aGVHD group 
was 37.5 years old, much higher compared with that of non- 
aGVHD patients (20.5 years old, p < 0.005; Table 2).
Individual variable analysis
The continuous variables were examined independently to 
test for a significance in difference between the two cohorts— 
aGVHD and non- aGVHD. Patient age did not reach signifi-
cance, but donor age was significantly different between 
these two cohorts, where older donor age was significantly 
associated with an increased risk of aGVHD (p  <  0.005; 
Table 2). Pharmaceutical monitoring factors associated with 
tacrolimus treatment, such as days to reach target levels (5 or 
10 ng/ml), number of readings below target levels, average 
trough levels, range of trough levels, and initial/final p.o.:i.v. 
conversion ratios, did not exhibit statistical significance be-
tween the aGVHD and non- aGVHD cohorts (p > 0.05).
For patients who developed aGVHD, the average starting 
i.v. dose by weight was 0.02 mg/kg (SD = 0.008), which is 
a standardized practice with rounding- up to the nearest tenth 
per protocol. When the patients were stabilized and able to 
take p.o. medication, i.v. tacrolimus was then transitioned to 
oral administration. The initial i.v. to p.o. conversion averaged 
1:2.9 and 1:2.7, in aGVHD and non- aGVHD patients, respec-
tively (p > 0.05 by t- test). The oral dose of tacrolimus was 
then adjusted based on serum trough levels detected. The final 
oral dosing of tacrolimus for maintenance before tapering off 
was ~ 2.5- fold the initial i.v. dose on average in patients with 
aGVHD, whereas such ratio was much higher in non- aGVHD 
patients (4.7- fold). Given the limited patients, however, this 
difference was not statistically significant (p > 0.05; Table 2).
In addition, the average trough levels of aGVHD and 
non- aGVHD patients were 7.4 and 7.2 ng/ml, respectively, 
with notable interpatient variabilities (Table  2). There was 
a trend for the non- aGVHD cohort to have more subthera-
peutic readings, where the average percentage of trough level 
readings less than 5 ng/ml were 30.7% in the aGVHD cohort 
and 35.5% in the non- aGVHD cohort. However, such differ-
ence did not reach statistical significance (p > 0.05). There 
were 76.8% and 78.8% of trough readings below 10 ng/ml for 
aGVHD and non- aGVHD cohorts, respectively (p > 0.05). 
For patients who developed aGVHD, it took an average of 
2.9 days to reach a target serum level of 5 ng/ml or higher, 
which was shorter than those who did not develop aGVHD 
(3.5 days). To reach a level above 10 ng/ml, it took an aver-
age of 6.1 days in patients with aGVHD and 8.6 days for the 
non- aGVHD cohort (p  >  0.05). Such difference (<3  days) 
may not exhibit clinical significance in patient care practice.
Likewise, the categorical variables were tested individu-
ally for significance. No differences were identified in patient 
gender, donor/recipient gender matching, presence of liver 
toxicity, nor clinical diagnosis (Table 3). Among donor rela-
tionships, a significant difference was demonstrated between 
sibling donors compared with parent donors (p < 0.005).
Power analysis
Using our collected data, a G- Power analysis for sample size 
calculation was conducted.18 For example, in order to detect 
a statistically significant difference between non- aGVHD 
and aGVHD patients on the average recorded serum level 
of tacrolimus (7.188 ng/ml ± 1.556 vs. 7.496 ng/ml ± 1.317, 
respectively), a sample size of 788 was calculated to be suf-
ficient to attain a power of 80% with a significant level of 
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0.05. For the “percent of readings <5 ng/mL,” our calculated 
sufficient sample size was 506 in order to detect statistically 
significance with a power of 80%. However, to conduct a ret-
rospective study with such a big sample size is challenging, 
particularly for pediatric patients who received HSCT.
Further post hoc t- test power calculations with using the 
sample sizes in this study indicate with an effect size d = 0.80 
power is 0.60.18 The power is lowered when the distributions 
are skewed, necessitating the use of the Wilcoxon Mann– 
Whitney test. Effect sizes are shown in Table  2, indicating 
areas that may warrant further study. However, in our study, 
there is sufficient power to obtain significance with large ef-
fect sizes (26 subjects are needed to achieve 82% power with 
an effect size of 1.18 using G- power), so the large effect size 
and statistical significance of donor age merit attention de-
spite our small sample size. In addition, we also gathered 
information on the magnitude of effect on these other mea-
sures to help with future multi- center and prospective studies.
Logistic regression model
After the model selection process and backward elimination, 
the only significant factor remaining in our model analysis was 
donor age (p < 0.01; Table 4). When donor age was removed 
from the model, donor relationship remained as a significant 
variable associated with aGVHD risk (p < 0.005; Table 4). In 
either of the reduced models, donor age or relationship, donor 
gender match was the final variable removed from the model. 
Applying a likelihood ratio test in either of the reduced models 
demonstrated that donor gender match had p values of 0.06 and 
0.07, when compared with the models without gender match.





means ± SDs Test statistic (95% CI)a DF p value
Effect size
(d, 95% CI)c 
Age 13.641 ± 6.711 14.676 ± 6.337 t = −0.455 (−5.68 to – 3.61) 30.562 0.652 0.15
(−0.56 to – 0.86)
Donor ageb 20.533 ± 11.288 37.500 ± 15.595 t = −3.486 (−26.949 to −6.984) 27.311 0.002 1.18
(0.41– 1.95 )
Weight 58.425 ± 31.991 59.188 ± 28.702 t = −0.072 (−22.42 to – 20.88) 30.127 0.943 0.02
(−0.69 to – 0.73)
Dose by weight, mg/kg 0.020 ± 0.008 0.018 ± 0.004 U = 139 0.928 0.02
(−0.35 to – 0.36)
Average recorded serum level 7.188 ± 1.556 7.496 ± 1.317 t = −0.612 (−1.337 to – 0.721) 29.484 0.545 0.20
(−0.51 to – 0.91)
Days to >5 ng/ml 3.562 ± 2.529 2.882 ± 1.409 U = 145.5 0.731 0.06
(−0.29 to – 0.38)
Days to >10 ng/ml 8.688 ± 9.864 6.062 ± 5.651 U = 155.5 0.304 0.18
(−0.17 to – 0.51)
Percent of readings <5 ng/ml 35.518 ± 19.386 30.739 ± 16.941 t = 0.752 (−0.082 to – 0.178) 29.853 0.458 0.25
(−0.46 to – 0.96)
Percent of readings <10 ng/ml 78.832 ± 18.889 76.785 ± 12.066 U = 161.5 0.368 0.16
(−0.17 to – 0.51)
Initial p.o. to i.v. conversion 
ratio
2.705 ± 1.416 2.879 ± 0.963 t = −0.394 (−1.085 to – 0.737) 24.667 0.697 0.14
(−0.58– 0.85)
Final p.o. to i.v. conversion 
ratio
4.743 ± 4.394 2.583 ± 1.796 U = 141 0.244 0.21
(−0.13– 0.53)
Percentage of allele match 
between donor and receipts, 
%
58.333 ± 14.247 60.784 ± 16.730 U = 126 0.697 −0.07
(−0.40 to – 0.29)
Tacrolimus trough level range, 
ng/ml
16.631 ± 6.465 15.200 ± 6.113 U = 156 0.482 0.13
(−0.25 to – 0.46)
Bold indicates the statistical significant values.
Abbreviations: aGVHD, acute graft- versus- host disease; CI, confidence interval; DF, degree of freedom; HSCT, hematopoietic stem cell transplantation.
aA Welch t- test was used for continuous variables unless normal distribution assumptions were not met in which case a Wilcoxon Mann– Whitney test was substituted. 
bThis is confounded by whether the donor is a parent or a sibling. 
cA Cohen’s d was computed for comparisons using a t- test and an r statistic for comparisons using a Wilcoxon Mann– Whitney test.46– 48 
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To further confirm the importance of potential confound-
ing factors included in our regression model, a partial least 
squares discriminant analysis was conducted. The highest 
variance was explained using a two- factor model as shown 
in Figure 1. The first component explains 13% of the vari-
ance and adding the second component only yields an addi-
tional 4%. The largest factor loading of the first component 
is the donor age, indicating that this variable had the highest 
relative importance in discriminating between patients who 
develop aGVHD from those that do not. The factor loading 
for this variable was −0.64, whereas the next closest variable 
was 0.36. This supports our findings that were demonstrated 
by using the logistic regression model, suggesting that donor 
age was associated with significantly higher risk of develop-
ing aGVHD in pediatric patients with HSCT. Notably such 
risk of aGVHD post- HSCT was independent of the allele 
matching between donor and recipient.
Our main statistical test was a single regression model at-
tempting to predict aGVHD using multiple predictors. Secondary 
to this approach, each variable was assessed separately in order 
to examine its relationship to aGVHD and stimulate further re-
search. The developed model is a type 1a prediction model, where 
the predictive performance was directly evaluated using the same 
study data.19 Effect sizes and confidence intervals were included 
to further assess the cost and feasibility of such a study based on 
the sample sizes needed. Because this investigation is exploratory 
in nature, we did not correct for multiple testing. The inclusion of 
confidence intervals allows other researchers to draw their own 
conclusions regarding the strength of the findings.
DISCUSSION
Allogeneic HSCT is an important therapeutic option and a 
potentially curative procedure for a variety of malignant and 
nonmalignant severe conditions. Despite the advancement 
in pharmacology and the development of less toxic precon-
ditioning regimens, GVHD remains the most frequent and 
serious complication following allogeneic HSCT, which 
remarkably impacts a patient’s survival and quality of life. 
Previous studies showed that 22% to 44% of patients who 
underwent HSCT developed grades II to IV aGVHD post- 
transplantation from HLA- matched siblings even with 
tacrolimus prophylaxis treatment.13,20 How to reduce the in-
cidence of GVHD overall— acute and chronic— and its sever-
ity remains the biggest challenge for clinical professionals.21
This retrospective study aimed to determine the potential 
confounding risk factors associated with aGVHD in pediat-
ric patients who underwent HSCT using a logistic regres-
sion analysis and partial least squares discriminate analysis. 
Many clinical and pharmacological risk factors have been 
shown to be associated with development of aGVHD in pe-
diatric transplant patients, such as patient age, total body 
irradiation, diagnosis at transplantation, donor/recipient 
gender, and graft source.2,22 A study compared potential 
risk factors associated with aGVHD and chronic GVHD 
in over 2900 adult and pediatric patients who received al-
logeneic hematopoietic cell transplantation and found that 
RR (95% CI) p value
Gender 1.048 (0.522– 2.104) 1.0
Donor Sibling: parents 3.569 (1.264 10.067) 0.00385
Sibling: unrelated 2.333 (0.422– 12.911) 0.450




Hepatic toxicity 1.413 (0.610– 3.271) 0.465
Diagnosis group b 0.165
Bold indicates the statistical significant values.
Notes: The only variable that appears significantly different between the aGVHD groups is the donor relation.
Abbreviations: aGVHD, acute graft- versus- host disease; CI, confidence interval; HSCT, hematopoietic stem 
cell transplantation; RR, relative risk.
aFisher’s Exact test.
bIndividual RR not included due to multiple comparisons and nonsignificant value.
T A B L E  3  Statistical analysis of the 
association of categorical variables with 
risk of aGVHD in pediatric patients who 
underwent HSCTa
T A B L E  4  Logistic regression model after backward elimination 
using the best fit model: donor relation run with donor age removed
Variable
Odds 
ratio CI Z- value p value
Donor age 1.088 1.030– 1.168 2.707 0.007
Donor relation: 
parent- siblinga 
0.084 0.013– 0.412 −2.859 0.004
Donor relation: 
parent- unrelated
0.308 0.010– 8.973 −0.773 0.440
Bold indicates the statistical significant values.
Abbreviation: CI, confidence interval.
aSignificant when run separately from donor age. 
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recipient HLA mismatching and the use of unrelated donors 
exhibited a greater risk of aGVHD.22 For pediatric patients, 
limited studies showed that older donor age and female 
donor sex were particularly associated with increased rate 
of aGVHD.23,24
In our study, only two patients received transplantation 
from unrelated donors; all the other donors were related, 
being either parents or siblings of the recipient. Further anal-
ysis demonstrated that among the related donors, both the 
donor relation and the donor’s age were significantly related 
to the development of aGVHD. These two factors— donor’s 
age and relation— could not be analyzed separately in our 
study, because all but two of our patients were either siblings 
or parents. However, both variables are independent of HLA 
allele matching status and gender matching. The parent do-
nors, ranging from 25 to 59 years old, exhibited a relatively 
higher aGVHD risk of 3.5 times compared with that of sib-
ling donors (2– 24 years old). Our finding of an older donor’s 
age being a significant predictive factor of aGVHD in pedi-
atric patients with HSCT with related donor was consistent 
with an early study reported by Mori’s et al.25
It is well- documented that tacrolimus exhibits significant 
pharmacological interpatient and intrapatient variability. 
Such variability necessitates the collection of serial trough 
concentrations to ensure that the drug remains within the 
targeted therapeutic range to minimize the risk of aGVHD. 
The metabolism of tacrolimus is further complicated by 
the developmental stages of pediatric patients,26 CYP3A5 
genotype,11,27 race/ethnicity,28 concomitant CYP- inducing 
medications, such as antifungals, and dosing regimen.29 
The clearance of tacrolimus has shown to be age- dependent, 
with children younger than 5 years old exhibiting a higher 
weight- normalized clearance compared with older children 
and adults.30
In current practice, the drug monitoring of tacrolimus is 
based on its serum trough levels and the dosage is adjusted to 
maintain the target serum levels between 5 and 15 ng/ml. As 
previously mentioned, target serum levels are varied among 
different institutions and guidelines.8 Interpreting tacroli-
mus serum levels and the associated risk of toxicities, such 
as nephrotoxicity, has been studied well.20 Yet, only a few 
studies in children have evaluated the relationship between 
the serum trough levels of tacrolimus and the occurrence of 
aGVHD, and the relationship remains controversial and in-
conclusive. There were studies suggesting that a higher target 
tacrolimus level post- transplant was associated with reduced 
risk of aGVHD.25,31,32 The cutoff or target trough levels var-
ied among different studies, ranging from 7 to 20 ng/ml in 
children post- allogeneic bone marrow transplantation.8,10,31,33 
One study demonstrated that every decrease of 1 ng/ml in tac-
rolimus mean concentrations over weeks 2– 3 post- transplant 
leads to an ~ 13% increased incidence of aGVHD.34 On the 
contrary, certain reports failed in identifying a relationship 
between the blood concentrations of tacrolimus and the oc-
currence of aGVHD in children.20
Another notable observation of our study is that we failed 
to demonstrate a significant impact of the target trough lev-
els of tacrolimus on the development of aGVHD, nor was it 
affected by the time to reach target levels. The treatment and 
monitoring plans after transplantation were standardized in 
the study institution and implemented by oncology pharma-
cists, which minimized the potential discrepancies associated 
with tacrolimus dosing and monitoring. In our retrospective 
study, 17 (- %) patients who underwent HSCT on tacrolimus 
F I G U R E  1  Visualization of significant variables within the best fit model and the accounted variance. (a) The aGVHD status in relation to 
donor age and relationship: each point is representative of a donor. Orange points represent donors associated with patients with aGVHD, whereas 
blue points represent donors associated with non- aGVHD patients. (b) Two- factor model demonstrating the highest variances associated with the 
development of aGVHD in pediatric patients with allogeneic HSCT: component 1 (X axis) explains 13% of the variance for increased aGVHD risk. 
The addition of component 2 (Y axis) accounts for an additional 4% of the variance. aGVHD, acute graft- vs.- host disease; HSCT, hematopoietic 
stem cell transplantation
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treatment experienced aGVHD, despite the fact that ~ 70% 
of trough levels were above the therapeutic target of 5 ng/ml. 
Neither the mean serum trough level nor the time to reach 
target level (≥5 ng/ml or ≥10 ng/ml) was shown to be asso-
ciated with the risk of aGVHD among our studied pediatric 
patients.
Area under the concentration- time curve (AUC) is gen-
erally used as the PK exposure parameter after an oral ad-
ministration, which is shown to be best associated with 
clinical outcomes.29,35,36 Notably, PK studies demonstrated 
that the trough levels of tacrolimus correlates poorly with 
the AUC0– 12,
37 suggesting a calculated AUC based on two 
measured serum levels may provide a more precise and cost- 
effective model for tacrolimus monitoring. However, to the 
best of our knowledge, very limited prospective studies have 
been conducted in pediatric transplant recipients to deter-
mine the potential benefits of AUC0– 12 monitoring compared 
with trough level- guided pharmacotherapy. An earlier study 
revealed that the AUC0– 12 after the first oral dose of tacroli-
mus was significantly lower in heart transplantation recipi-
ents who experienced acute rejection compared with those 
who did not.38
PK studies demonstrated distinct metabolic profiles 
among patients, which may result in significant difference 
in drug exposure.39,40 Simply monitoring trough levels may 
limit its capacity to precisely guide and optimize the tacro-
limus therapy. Most of the comparison studies of different 
tacrolimus formulations utilized AUC instead of trough lev-
els to compare the efficacy of tacrolimus.35,36 Consistently, 
the final p.o. to i.v. ratio of tacrolimus was much higher in 
non- aGVHD patients compared with that of the patients 
who developed aGVHD (4.9- fold and 2.5- fold of i.v. dos-
ing, respectively), yet, we failed to observe any significant 
changes of the average trough levels between the two groups. 
A prospective study to investigate the association between 
tacrolimus AUC and clinical outcomes, such as incidence of 
aGVHD and patient’s survival, is greatly warranted.
In general, patients with HSCT were initiated tacroli-
mus therapy as a continuous i.v. infusion. After the patient 
reached the target level and was capable of oral intake, tac-
rolimus was then converted to p.o., which continued until 
at least day +90 and was tapered off by day +180 post- 
transplant. The pediatric dosage of tacrolimus is generally 
individualized based on patient body weight, which is much 
smaller compared with the adult dose. Current available 
oral dosage forms are limited to capsule and tablet forms, 
which are not feasible for pediatric patients, especially 
younger children. As a general practice, many children’s 
hospitals are compelled to extemporaneously compound 
oral solutions using immediate- release capsules. Of note, 
tacrolimus is a National Institute for Occupational Safety 
and Health- listed hazardous drug requiring special han-
dling when compounding extemporaneously.41 As such, 
there is an urgent need of developing an age- appropriate, 
safe, and effective formulation of tacrolimus for pediatric 
patients.
In addition, the prophylaxis efficacy of tacrolimus may 
be affected by distinct combination regimens, such as siro-
limus, mycophenolate, and methotrexate.42,43 In our study 
institution, the most commonly used GVHD prophylaxis 
regimen was the combination of tacrolimus, mycophenolate, 
and cyclophosphamide (30/33, 91%), which minimized the 
need to examine the potential effects of different regimens on 
patient’s risk of aGVHD.
Importantly, in earlier studies of patients with HSCT, 34– 
78% using tacrolimus, either alone or in combination, cumula-
tively developed nephrotoxicity during the first 100 days after 
marrow transplantation.12,13 However, in our retrospective 
study, no significant nephrotoxicity was identified. The over-
all lower incidence of nephrotoxicity in our study may be re-
lated to the lower levels of tacrolimus (5– 15 ng/ml) that were 
maintained in our study population and the low target level of 
5 ng/ml as recommended by the institution. One study sug-
gested that the risk of nephrotoxicity was markedly increased 
when the mean trough level over 14  days was greater than 
or equal to 20 ng/ml.20 Our patients rarely exceeded trough 
levels greater than or equal to 20 ng/ml with pharmacist- led 
drug therapy monitoring practice (<1% of all the documented 
levels). In the event of greater than or equal to 20 ng/ml, tac-
rolimus doses were quickly reduced or placed on hold.
A potential limitation is the nature of a single- institution 
retrospective cohort study, which restricts the number of el-
igible patients and reduces the power for statistical analysis. 
Pediatric cancer incidences are generally lower than adults. 
Approximately 0.61% of new cancer cases in the United 
States in 2020 will be pediatric patients aged 0– 14  years 
old, and of that, 28% will be leukemia.44 There is also an 
increasing rate of pediatric patients achieving remission; for 
example, the 5- year survival rate for children with acute lym-
phoblastic leukemia has now greatly increased to about 90% 
overall. HSCT is reserved for relapsed or refractory patients 
who failed other treatments, so the total number of patients 
meeting our study criteria will be much smaller compared 
with other similar studies conducted in adult patients. That 
explains why similar studies with pediatric patients are lim-
ited with patient sample size (22– 55 patients).9,30,45 Due 
to the relatively small sample size and the large number of 
predictors, this study should be considered exploratory. The 
small sample size creates a higher risk of both type I and type 
II errors. Type I errors could occur if our population was sys-
tematically different from the population. The possibility of 
type II errors is increased as the power of this study makes it 
difficult to detect moderate or small effect sizes, which may 
be clinically significant. Based on the TRIPOD guidelines by 
Collins et al., this study falls under the type 1a: development 
only model, which suggests that our results could be improved 
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with an enlarged patient sample size and a multicenter study 
to validate and refine our predictive risk factor model.19 The 
data generated from this study is critical for power analysis, 
which will allow us to better estimate the adequate sample 
size relative to the study goals and the possible variabilities 
of the study, in order to optimize the study design.
CONCLUSION
Our single- institution retrospective cohort study demon-
strated that the risk of aGVHD was significantly increased 
with parent donors and/or donors older in age among pediat-
ric patients receiving allogeneic HSCT from matched- related 
donors. We failed to observe a significant decisive role of 
pharmacological factors associated with tacrolimus treat-
ment in a patient’s risk of aGVHD, although some studies 
indicated that these factors may play a role in aGVHD.8,12 
Further prospective studies in a larger, more racially diverse 
cohort to investigate these finding are warranted.
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